Immunoliposome-based targeted delivery of the CRISPR/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival

참고문헌 (63)

1. Siegel, R. L., "Cancer statistics", CA Cancer J. Clin, 72, pp.7~33 (2022)
2. Cheng, Z., "Nanomaterials for cancer therapy : current progress and perspectives", J. Hematol. Oncol, 14, pp.85~ (2021)
3. Liu, P., "A review of liposomes as a drug delivery system : current status of approved products, regulatory environments, and future per spectives", Molecules, 27, pp.1372~ (2022)
4. Sonju, J. J., "Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment", J. Control. Release, 329, pp.624~644 (2021)
5. Markowski, A., "Novel liposomal formulation of baicalein for the treatment of pancreatic ductal adenocarcinoma : design, characterization, and evaluation", Pharmaceutics, 15, pp.179~ (2023)
6. Pflanz, S., "IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells", Immunity, 16, pp.779~790 (2002)
7. Di Meo, S., "Interleukin-30 expression in prostate cancer and its draining lymph nodes correlates with advanced grade and stage", Clin. Cancer Res, 20, pp.585~594 (2014)
8. Airoldi, I., "Interleukin-30 promotes breast cancer growth and progression", Cancer Res, 76, pp.6218~6229 (2016)
9. Sorrentino, C., "Interleukin-30", IL27p28 shapes prostate cancer stem-like cell behavior and is critical for tumor onset and metastasization, 2018, pp.78, 2654~2668
10. Müller, S. I., "A folding switch regulates interleukin 27 biogenesis and secretion of its α-subunit as a cytokine", Proc. Natl Acad. Sci. USA, 116, pp.1585~1590 (2019)
11. Sorrentino, C., "Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome", J. Immunother. Cancer, 9, pp.e002966~ (2021)
12. Sorrentino, C., "CRISPR", Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mor tality, 2022, pp.15, 145~
13. Knott, G. J., "CRISPR-Cas guides the future of genetic engineering", Science, 361, pp.866~869 (2018)
14. Kaushik, I., "CRISPR-Cas9 : a multifaceted therapeutic strategy for cancer treatment", Semin. Cell. Dev. Biol, 96, pp.4~12 (2019)
15. Stone, K. R., "Isolation of a human prostate carcinoma cell line(DU 145)", Int. J. Cancer, 21, pp.274~281 (1978)
16. Tai, S., "PC3 is a cell line characteristic of prostatic small cell carcinoma", Prostate, 71, pp.1668~1679 (2011)
17. Foster, B. A., "Char acterization of prostatic epithelial cell lines derived from transgenic adenocarci noma of the mouse prostate(TRAMP)model", Cancer Res, 57, pp.3325~3330 (1997)
18. Brinkman, E. K., "Rapid quantitative evaluation of CRISPR gen ome editing by TIDE and TIDER", Methods Mol. Biol, 1961, pp.29~44 (2019)
19. Conant, D., "Inference of CRISPR edits from Sanger trace data", CRISPR J, 5, pp.123~130 (2022)
20. Gu, Z., "Prostate stem cell antigen(PSCA)expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer", Oncogene, 19, pp.1288~1296 (2000)
21. Lam, J. S., "Prostate stem cell antigen is overexpressed in prostate cancer metastases", Clin. Cancer Res, 11, pp.2591~2596 (2005)
22. Ghosh, S., "Nanomaterials Safety: Toxicity And Health Hazards", pp.207~214 (2019), De Gruyter
23. Ritsma, L., "Intravital microscopy through an abdominal imaging window reveals a pre-micrometastasis stage during liver metastasis", Sci. Transl. Med, 4, pp.158ra145~ (2012)
24. Nguyen, D. P., "Recent insights into NF-κB sig nalling pathways and the link between inflammation and prostate cancer", BJU Int, 114, pp.168~176 (2014)
25. Schmitz, M., "Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis", Int. J. Cancer, 120, pp.1284~1292 (2007)
26. van Berlo, D., "10% Body weight(gain)change as criterion for the maximum tolerated dose : a critical analysis", Regul. Toxicol. Pharmacol, 134, pp.105235~ (2022)
27. Sorrentino, C., "Hindering triple negative breast cancer progression by tar geting endogenous interleukin-30 requires IFNγ signaling", Clin. Transl. Med, 11, pp.e278~ (2021)
28. Taniguchi, K., "NF-κB, inflammation, immunity and cancer : coming of age", Nat. Rev. Immunol, 18, pp.309~324 (2018)
29. Waldman, A. D., "A guide to cancer immunotherapy : from T cell basic science to clinical practice", Nat. Rev. Immunol, 20, pp.651~668 (2020)
30. Sorrentino, C., "Targeting Interleukin(IL)-30", IL-27p28 signaling in cancer stem like cells and host environment synergistically inhibits prostate cancer growth and improves survival, 2019, pp.7, 201~
31. Doudna, J. A., "Genome editing. The new frontier of genome engineering with CRISPR-Cas9", Science, 346, pp.1258096~ (2014)
32. Kanduri, V., "Current advances toward the encapsulation of Cas9", ACS Macro Lett, 10, pp.1576~1589 (2021)
33. Immordino, M. L., "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential", Int. J. Nanomed, 1, pp.297~315 (2006)
34. Andresen, T. L., "Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release", Prog. Lipid Res, 44, pp.68~97 (2005)
35. Suk, J. S., "PEGylation as a strategy for improving nanoparticle-based drug and gene delivery", Adv. Drug Deliv. Rev, 99, pp.28~51 (2016)
36. Du, Z., "The role of the helper lipid on the DNA transfection efficiency of lipopolyplex formulations", Sci. Rep, 4, pp.7107~ (2014)
37. Marques, A. C., "Lipid nanoparticles functiona lized with antibodies for anticancer drug therapy", Pharmaceutics, 15, pp.216~ (2023)
38. Ciummo, S. L., "Interleukin-30 subverts prostate cancer-endothelium crosstalk by fostering angiogenesis and activating immunoregulatory and oncogenic signaling pathways", J. Exp. Clin. Cancer Res, 42, pp.336~ (2023)
39. Jacobo, S. M., "Insulin-like growth factor 1 (IGF-1) stabilizes nas cent blood vessels", J. Biol. Chem, 290, pp.6349~6360 (2015)
40. Hall-Glenn, F., "CCN2", connective tissue growth factor is essential for pericyte adhesion and endothelial basement membrane formation during angiogenesis, 2012, pp.7, e30562~
41. Keeley, E. C., "CXC chemokines in cancer angiogenesis and metastases", Adv. Cancer Res, 106, pp.91~111 (2010)
42. Bagnato, A., "Emerging role of endothelin-1 in tumor angiogenesis", Trends Endocrinol. Metab, 14, pp.44~50 (2003)
43. Nakagawa, T., "Inhibition of angiogenesis and tumor progression of MK-0429, an integrin αvβ3 antagonist, on oral squamous cell carcinoma", J. Cancer Res. Clin. Oncol, 148, pp.3281~3292 (2022)
44. Sainson, R. C., "TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype", Blood, 111, pp.4997~5007 (2008)
45. Quintero-Fabián, S., "Role of matrix metalloproteinases in angiogenesis and cancer", Front. Oncol, 9, pp.1370~ (2019)
46. Murakami, M., "Fibroblast growth factor regulation of neovascular ization", Curr. Opin. Hematol, 15, pp.215~220 (2008)
47. Iñiguez, M. A., "Cycloox ygenase-2 : a therapeutic target in angiogenesis", Trends Mol. Med, 9, pp.73~78 (2003)
48. Pećina-Slaus, N., "Tumor suppressor gene E-cadherin and its role in normal and malignant cells", Cancer Cell. Int, 3, pp.17~ (2003)
49. Kardooni, H., "CRISPR-mediated reactivation of DKK3 expression attenuates TGF-β Signaling in prostate cancer", Cancers, 10, pp.165~ (2018)
50. Lee, E. J., "Dickkopf-3 in human malignant tumours: a clinical viewpoint", Anticancer Res, 40, pp.5969~5979 (2020)
51. Chen, C. Y., "PTEN : tumor suppressor and metabolic regulator", Front. Endocrinol, 9, pp.338~ (2018)
52. Karpisheh, V., "The role of regulatory T cells in the pathogenesis and treat ment of prostate cancer", Life Sci, 284, pp.119132~ (2021)
53. Irshad, S., "RORγt+ innate lymphoid cells promote lymph node metastasis of breast cancers", Cancer Res, 77, pp.1083~1096 (2017)
54. Koh, J., "IL23-producing human lung cancer cells promote tumor growth via conversion of innate lymphoid cell 1(ILC1)into ILC3", Clin. Cancer Res, 25, pp.4026~4037 (2019)
55. Bal, S. M., "Plasticity of innate lymphoid cell subsets", Nat. Rev. Immunol, 20, pp.552~565 (2020)
56. Bergers, G., "Modes of resistance to anti-angiogenic therapy", Nat. Rev. Cancer, 8, pp.592~603 (2008)
57. Haibe, Y., "Resistance mechanisms to anti-angiogenic therapies in cancer", Front. Oncol, 10, pp.221~ (2020)
58. Lee, W. S., "Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity", Exp. Mol. Med, 52, pp.1475~1485 (2020)
59. Sharma, R., "Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma", J. Exp. Clin. Cancer Res, 40, pp.186~ (2021)
60. Beltrán-Gracia, E., "Nanomedicine review : clinical developments in liposomal applications", Cancer Nano, 10, pp.11~ (2019)
61. Rommasi, F., "Liposomal nanomedicine : applications for drug delivery in cancer therapy", Nanoscale Res. Lett, 16, pp.95~ (2021)
62. Rehman, L. U., "Immunotherapy for prostate cancer : a current systematic review and patient centric perspectives", J. Clin. Med, 12, pp.1446~ (2023)
63. Sorrentino, C., "Molecular targeted therapies in metastatic prostate cancer : recent advances and future challenges", Cancers, 15, pp.2885~ (2023)

관련 논문AI추천